Skip to main content

It looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.

Switch to US ($)
Scientist validating custom monoclonal antibody production in the ProteoGenix laboratory

Custom Monoclonal Antibody Production Services

Test your antibody in your own lab before final acceptance.

Develop custom monoclonal antibodies for diagnostics and research with guaranteed performance in 11 applications. Validate the antibody in your own laboratory under your experimental conditions before final acceptance

Request a Quote

  • 4 Discovery Platforms

    Hybridoma • Phage Display • Single B-Cell • AI de novo

  • Any Antigen Accepted

    Proteins • PTMs • Peptides • Whole Cells • Haptens

  • 11 Applications Guaranteed

    ELISA • WB • IHC • FACS • LFA …

  • Test It
    in Your Lab

    Validate the antibody
    before final acceptance.

Guaranteed custom monoclonal antibody performance across 11 applications

Your antibody, validated in the assay that matters to you. Every custom monoclonal antibody we produce is screened and delivered with performance data in your target application — tested in your own lab, under your own conditions, before you pay in full.

  • Standard ELISA

  • Sandwich ELISA

  • Flow cytometry (FACS)

  • Immunohistofluorescence

  • Immunofluorescence

  • Lateral flow assay (LFA)

  • Competitive ELISA

  • Immunoprecipitation

  • Modification-specific detection

  • Western Blot

  • Immunohistochemistry

Validate the antibodies in your own lab before paying in full

You test the custom monoclonal antibodies under your real experimental conditions before validating the final delivery — so you only pay in full for antibodies that work where you need them.

  • ProteoGenix validation

    We test the antibodies in their final application.

  • Your lab test

    You test the antibodies under your own experimental conditions.

  • Pay If Satisfied

    You only pay the full project fee if you are satisfied.

Request a Quote Talk to an Antibody Expert

No Antigen Too Complex

From standard recombinant proteins to the most structurally demanding targets — our multi-platform approach is engineered to handle diversity at every level.

  • Recombinant proteins

    Including challenging targets such as membrane proteins (GPCRs, ion channels), multi-domain complexes, and low-immunogenicity antigens.

  • Peptides

    Ideal for high specificity, PTM detection, or when the protein is unavailable.

  • Post-translational modifications

    Phosphorylation, acetylation, methylation… with modified vs. unmodified antibody validation.

  • Haptens & small molecules

    Conjugated to KLH or BSA. From pesticides, steroids and toxins to lipids, nucleotides, amino acids and saccharides…

  • Whole cells & VLPs

    Cell-based immunization and panning for membrane proteins in native conformation.

  • DNA constructs

    Useful when the protein is hard to produce. Combines advantages of protein and peptide immunization.

Discovery platforms
4 Proven Routes to Your Custom Monoclonal Antibody

  • 45 days

    Hybridoma

    The gold standard for diagnostic and research-grade antibodies.

    • Best for diagnostics
    • >90% success rate
    • 11 guaranteed applications

  • <2 weeks

    Phage Display

    Fast in vitro selection from high-diversity antibody libraries.

    • No immunization required
    • 200B+ ScFv libraries
    • 3 guaranteed binders

  • 6 weeks

    Single B-Cell

    Recover naturally paired VH/VL sequences from rare antigen-specific cells.

    • Rare epitopes
    • High-value targets
    • 3 guaranteed clones

  • 2–3 days

    AI de novo

    Novel antibody sequences designed in silico and validated experimentally.

    • No animal model needed
    • Predictive design
    • No win, no fee

Platform Hybridoma Phage Display Single B-Cell AI de novo
Typical Timeline 45 days 2 weeks 6 weeks 2-3 days
Animal immunization Required Not required Required Not required
Species available Mouse, Rat, Rabbit, Guinea pig, Llama, Alpaca, Camel, Cow, Dog, Cat, Swine, Horse, Humanized mice Human, Rabbit, Camelid, Dog, Cat, Custom library generation possible Mouse, Rat, Rabbit, Guinea pig, Llama, Alpaca, Camel, Cow, Dog, Cat, Swine, Horse, Humanized mice All species
Best for difficult targets ★★ ★★★ ★★★ ★★★
Guarantee > 90% success rate, 11 guaranteed applications 3 guaranteed binders 3 guaranteed clones, 11 guaranteed applications No win No fee
Ideal use case Diagnostics, research Human research tools, fast leads Rare epitopes, high-value targets, Diagnostics, research No animal model available

A simple, integrated workflow
End to End

Whatever your target, species, or format — every project follows the same clear, managed path with a single expert partner from start to delivery.

1.

Define & Design

We discuss your target and goals, then design and produce the optimal antigen.

2.

Discover

Antibodies generated via the best-fit platform with a custom strategy: hybridoma, phage, single B-cell or AI.

3.

Engineer (optional)

Engineering or conjugation to fit your chosen format.

4.

Production & Validation

Affinity, specificity and functionality characterized in your application of interest.

5.

Deliver

Final antibodies, sequences and full report.

Complete, ready-to-use deliverables

Every project comes with everything you need to use, publish, and continue developing your antibody independently.

  • Purified antibody

    Specified amount of purified mAb, QC-checked by SDS-PAGE and ELISA

  • Application data

    Performance report in your target application: ELISA titer, WB band, IHC staining,…

  • Cell line / sequences

    Hybridoma cell line and/or VH/VL sequences — full IP ownership with no strings attached

  • Full project report

    Detailed technical report with immunization data, screening results and QC records

Publications featuring our monoclonal antibodies

Publications

JP Barnier et al., The minor pilin PilV provides a conserved adhesion site throughout the antigenically variable meningococcal type IV pilus. PNAS 118, (45) e2109364118 (2021).
https://doi.org/10.1073/pnas.2109364118

Publications

H Cerutti et al., Large scale production and characterization of SARS-CoV-2 whole antigen for serological test development. J Clin Lab Anal 35, (4) 23735 (2021).
https://doi.org/10.1002/jcla.23735

Publications

PC Maity et al., IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. PNAS 117, (8) 4320-27 (2020).
https://doi.org/10.1073/pnas.1913810117

Publications

M Fresquet et al., Autoantigens PLA2R and THSD7A in membranous nephropathy share a common epitope motif in the N-terminal domain. J Autoimm 106, 102308 (2020).
https://doi.org/10.1016/j.jaut.2019.102308

Publications

P Cunha et al., Expansion, isolation and first characterization of bovine Th17 lymphocytes. Nature Sci Rep 9, 16115 (2019).
https://doi.org/10.1038/s41598-019-52562-2

Publications

M Krifa et al., Limoniastrum guyonianum aqueous gall extract induces apoptosis in human cervical cancer cells involving p16INK4A re-expression related to UHRF1 and DNMT1 down-regulation. J Exp Clin Canc Res 32, (30) (2013).
https://doi.org/10.1186/1756-9966-32-30

Publications

E Faure et al., Probable presence of an ubiquitous cryptic mitochondrial gene on the antisense strand of the cytochrome oxidase I gene. Biol Direct 6, (56) (2011).
https://doi.org/10.1186/1745-6150-6-56

FAQ about our custom monoclonal antibody production service

Why scientists choose ProteoGenix

Need a quote or more information? Contact us!

    Cart (0 Items)

    Your cart is currently empty.

    View Products